Aastrom Biosciences Inc. (ASTM) announced a U.S. Phase II IMPACT-DCM clinical trial interim data suggesting that the majority of patients treated to date with Cardiac Repair Cells or CRCs)have shown improvements in their heart failure classification, while patients in the control group, who did not receive CRCs, did not have a similarly improved outcome.
Of the 7 treatment patients who have completed the 1-month follow-up visit, 1 patient had improved to NYHA Class I and 3patients had improved to Class II. In contrast, at the 1-month follow-up visit, the NYHA Class did not improve in 3 of the 5 control patients.
Of the 6 treatment patients who have completed the 3-month follow-up visit, 1 patient improved to NYHA Class I and 2patients improved to Class II. In contrast, at the 3-month follow-up visit, the NYHA Class did not improve in 4 of the 5control patients.Of the 5 treatment patients who have completed the 6-month follow-up visit, 2 patients improved to NYHA Class I, 2 patients improved to Class II and 1 patient deteriorated to NYHA Class IV.
In contrast, at the 6-month follow-up visit, the NYHA Class did not improve in 3 of the 5 control patients, including 1 patient who deteriorated to NYHA Class IV.
For comments and feedback contact: editorial@rttnews.com
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.